Why women’s leadership matters in the age of AI
AI may become one of the most significant leadership opportunities for women in decades. Its impact will depend on how capability, governance, and leadership are built around it....
Tech for Good
ESG
Bioversys: ‘Impact investors should focus more on equitable health’
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of...
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics.
In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world.
Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business.
Expert
Authors
More to explore
ShareRebuilding trust in a bank that was once on shaky ground
Slawomir Krupa, CEO of Societe Generale, tells Jean-François Manzoni how restoring financial discipline and protecting the bank’s capacity to innovate under pressure helped restore faith in one of Europe’s oldest institutions...
Innovating tradition: Why redefining values keeps family legacy alive
Melisa Sabancı Tapan, in conversation with IMD’s Peter Vogel, discusses creating empowered communities, bringing the wisdom of the past to new generations through AI, and staying human in a digital world. ...